$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2018
[Report Updated: 13-03-2018]

Published by Global Markets Direct: 13 Mar 2018 | 203294 | In Stock
Related Topics: Healthcare , Infectious Disease

Introduction

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2018, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 4, 10, 1, 29 and 6 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 4 molecules, respectively.

Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
for Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2018 [Report Updated: 13-03-2018]

  • Table of Contents

    Table of Contents 2

    Introduction 5

    Influenza A Virus, H5N1 Subtype Infections - Overview 6

    Influenza A Virus, H5N1 Subtype Infections - Therapeutics Development 7

    Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment 17

    Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development 25

    Influenza A Virus, H5N1 Subtype Infections - Drug Profiles 39

    Influenza A Virus, H5N1 Subtype Infections - Dormant Projects 127

    Influenza A Virus, H5N1 Subtype Infections - Discontinued Products 131

    Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones 132

    Appendix 142

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

203294 | GMDHC10251IDB

Number of Pages

149

Report Format

PDF

Global Markets Direct Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Global Influenza Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Influenza B Infections Global Clinical Trials Review, H1, 2016
Influenza B Infections Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial rep...
20 Jan 2016 by Global Data USD $2,500 More Info
Pandemic Influenza Global Clinical Trials Review, H1, 2016
Pandemic Influenza Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report,...
20 Jan 2016 by Global Data USD $2,500 More Info
Influenza A Infections Global Clinical Trials Review, H1, 2016
Influenza A Infections Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial rep...
20 Jan 2016 by Global Data USD $2,500 More Info
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H1, 2016
H5N1 Infection (Avian Influenza) Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical...
20 Jan 2016 by Global Data USD $2,500 More Info
Swine Influenza Global Clinical Trials Review, H1, 2016
Swine Influenza Global Clinical Trials Review, H1, 2016SummaryGlobalData's clinical trial report, “S...
20 Jan 2016 by Global Data USD $2,500 More Info
Seasonal Influenza Global Clinical Trials Review, H2, 2015
Seasonal Influenza Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report,...
30 Dec 2015 by Global Data USD $2,500 More Info
Influenza A Infections Global Clinical Trials Review, H2, 2015
Influenza A Infections Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial rep...
30 Dec 2015 by Global Data USD $2,500 More Info
Pandemic Influenza Global Clinical Trials Review, H2, 2015
Pandemic Influenza Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial report,...
30 Dec 2015 by Global Data USD $2,500 More Info
Influenza B Infections Global Clinical Trials Review, H2, 2015
Influenza B Infections Global Clinical Trials Review, H2, 2015SummaryGlobalData's clinical trial rep...
30 Dec 2015 by Global Data USD $2,500 More Info

This report is published by Global Markets Direct

Download Free Report Summary PDF

Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H1 2018 [Report Updated: 13-03-2018] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...